Correction to: ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures (Journal of Nuclear Cardiology, (2016), 23, 5, (1187-1226), 10.1007/s12350-016-0522-3);ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures

Journal of Nuclear Cardiology

Volumn 23, Issue 5, 2016, Pages 1187-1226

  Dilsizian, Vasken ^a   Bacharach, Stephen L ^b   Beanlands, Rob S ^c   Bergmann, Steven R ^d   Delbeke, Dominique ^e   Dorbala, Sharmila ^f   Gropler, Robert J ^g   Knuuti, Juhani ^h   Schelbert, Heinrich R ⁱ   Travin, Mark I ^j  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h TURKU UNIVERSITY HOSPITAL   (Finland)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j MONTEFIORE MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA N 13; ANTIBIOTIC AGENT; FLUORODEOXYGLUCOSE F 18; RUBIDIUM 82; WATER O 15;

ARTICLE; ARTIFACT REDUCTION; BIOSTATISTICS; CALIBRATION; CARDIAC GATED IMAGING; CARDIOLOGY; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR EQUIPMENT; CARDIOVASCULAR INFECTION; CARDIOVASCULAR PROCEDURE; CARDITIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DEVICE INFECTION; DIABETIC PATIENT; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DOSIMETRY; DRUG APPROVAL; DRUG UPTAKE; FOOD AND DRUG ADMINISTRATION; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HEART LEFT VENTRICLE SIZE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE METABOLISM; HEART RIGHT VENTRICLE SIZE; HEART VENTRICLE SIZE; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE PROCESSING; IMAGE QUALITY; IMAGE RECONSTRUCTION; IMAGE SEGMENTATION; IMAGING SYSTEM; INFLAMMATORY CELL; INTERMETHOD COMPARISON; LABORATORY TEST; MEDICAL ERROR; MEDICAL SOCIETY; MYOCARDIAL PERFUSION IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PATIENT INFORMATION; PATIENT MOBILITY; PATIENT POSITIONING; PET SCANNER; PHARMACOLOGIC STRESS TESTING; POSITRON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY TIME OF FLIGHT IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY CONTROL PROCEDURES; RADIATION ATTENUATION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION SCATTERING; RADIOLOGICAL PARAMETERS; RADIOLOGICAL PROCEDURES; RADIOSENSITIVITY; SARCOIDOSIS; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL IMAGING; X RAY CAMERA; NUCLEAR MEDICINE; STANDARDS;

CARDIOLOGY; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY;

EID: 84978086884     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-023-03357-6     Document Type: Erratum

References (158)

1. Bacharach SL. Positron emission tomography. In: Dilsizian V, Pohost GM, editors. Cardiac CT, PET, and MR. 2nd ed. Hoboken: Wiley-Blackwell; 2010. p. 3-29.
2. Dilsizian V. 2014 SNMMI highlights lecture: Cardiovascular imaging. J Nucl Med 2014;55:9N–15N.
3. White JA, Rajchl M, Butler J, Thompson RT, Prato FS, Wisenberg G. Active cardiac sarcoidosis: First clinical experience of simultaneous positron emission tomography–magnetic resonance imaging for the diagnosis of cardiac disease. Circulation 2013;127:e639–41.
4. Dilsizian V, Bacharach SL, Beanlands SR, Bergmann SR, Delbeke D, Gropler RJ et al. ASNC Imaging Guidelines for Nuclear Cardiology Procedures: PET myocardial perfusion and metabolism clinical imaging. J Nucl Card 2009;16(4):651. American Society of Nuclear Cardiology website. http://www.asnc.org/files/PET%20MP%20&%20Glucose%20Metabolism%202009.pdf. Accessed December 15, 2015.
5. National Electrical Manufacturers Association. NEMA Standards Publication NU 2-2012. Performance measurements of positron emission tomographs. National Electrical Manufacturers Association website. http://www.nema.org/Standards/Pages/Performance-Measurements-of-Positron-Emission-Tomographs.aspx.
6. National Electrical Manufacturers Association. NEMA Standards Publication NU 2-1994. Performance measurements of positron emission tomographs. Washington, DC: National Electrical Manufacturers Association; 1994.
7. National Electrical Manufacturers Association. NEMA standards publication NU 2-2001. Performance measurements of positron emission tomographs. Washington, DC: National Electrical Manufacturers Association; 2001.
8. National Electrical Manufacturers Association. NEMA standards publication NU 2–2007. Performance measurements of positron emission tomographs. Rosslyn, VA: National Electrical Manufacturers Association; 2007.
9. American College of Radiology. ACR technical standard for medical nuclear physics performance monitoring of PET imaging equipment. Revised 2011 (Resolution 2). American College of Radiology website. http://www.acr.org/~/media/79b2f5688db3457fab228e311434abe8.pdf. Accessed November 20, 2015.
10. deKemp RA, Yoshinaga K, Beanlands RS. Will 3-dimensional PET-CT enable the routine quantification of myocardial blood flow? J Nucl Cardiol 2007;14:380–97.
11. Thomas L, Joel K. PET systems (Chapter 10). In: Wernick Miles N, Aarsvold John N, editors. Emission tomography. San Diego: Elsevier Academic Press; 2004. p. 179–94.
12. Lewellan T. Time-of-flight PET. Semin Nucl Med 1998;28:268–75.
13. Ter-Pogossian MM, Ficke DC, Yamamoto M, Hood JT. Super PETT I: a positron emission tomograph utilizing photon time-of-flight information. IEEE Trans Med Imaging 1982;1:179–87.
14. Yamamoto M, Ficke DC, Ter-Pogossian MM. Experimental assessment of the gain achieved by the utilization of time-of-flight information in a positron emission tomograph (Super PETT I). IEEE Trans Med Imaging 1982;1:187–92.
15. Suda M, Onoguchi M, Tomiyama T, Ishihara K, Takahashi N, Sakurai M, et al. The reproducibility of time-of-flight PET and conventional PET for the quantification of myocardial blood flow and coronary flow reserve with N-13 ammonia. J Nucl Cardiol 2015. doi:10.1007/s12350-015-0074-y.
16. Dorbala S, Di Carli MF, Delbeke D, Ishihara K, Takahashi N, Sakurai M, et al. SNMMI/ASNC/SCCT guideline for cardiac SPECT/CT and PET/CT 1.0. J Nucl Med 2013;54:1485–507.
17. Le Meunier L, Maass-Moreno R, Carrasquillo JA, Dieckmann W, Bacharach SL. PET/CT imaging: Effect of respiratory motion on apparent myocardial uptake. J Nucl Cardiol 2006;13:821–30.
18. American College of Radiology. ACR–AAPM technical standard for diagnostic medical physics performance monitoring of computed tomography (CT) equipment. Revised 2012 (Resolution 34). American College of Radiology website. http://www.acr.org/~/media/1C44704824F84B78ACA900215CCB8420.pdf. Accessed February 1, 2016.
19. Gould KL, Pan T, Loghin C, Johnson NP, Guha A, Sdringola S. Frequent diagnostic errors in cardiac PET/CT due to misregistration of CT attenuation and emission PET images: A definitive analysis of causes, consequences, and corrections. J Nucl Med 2007;48:1112–21.
20. Slomka PJ, Le Meunier L, Hayes SW, et al. Comparison of myocardial perfusion 82Rb PET performed with CT- and transmission CT-based attenuation correction. J Nucl Med 2008;49:1992–8.
21. Loghin C, Sdringola S, Gould KL. Common artifacts in PET myocardial perfusion images due to attenuation-emission misregistration: Clinical significance, causes, and solutions. J Nucl Med 2004;45:1029–39.
22. Alessio AM, Kohlmyer S, Branch K, Chen G, Caldwell J, Kinahan P. Cine CT for attenuation correction in cardiac PET/CT. J Nucl Med 2007;48:794–801.
23. Souvatzoglou M, Bengel F, Busch R, Kruschke C, Fernolendt H, Lee D, et al. Attenuation correction in cardiac PET/CT with three different CT protocols: A comparison with conventional PET. Eur J Nucl Med Mol Imaging 2007;34:1991–2000.
24. DiFilippo FP, Brunken RC. Do implanted pacemaker leads and ICD leads cause metal-related artifact in cardiac PET/CT? J Nucl Med 2005;46:436–43.
25. Hamill JJ, Brunken RC, Bybel B, DiFilippo FP, Faul DD. A knowledge-based method for reducing attenuation artefacts caused by cardiac appliances in myocardial PET/CT. Phys Med Biol 2006;51:2901–18.
26. Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J Nucl Cardiol 2016;23:606–39.
27. Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, et al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol 2007;14:514–20.
28. Johnson NP, Gould KL. Regadenoson versus dipyridamole hyperemia for cardiac positron emission tomography imaging. JACC Cardiovasc Imaging 2015;8:438–47.
29. Dilsizian V, Narula J. Capturing maximal coronary vasodilation for myocardial perfusion imaging: Timing is everything. JACC Cardiovasc Imaging 2015;8:499–500.
30. Sinusas AJ. Does a shortened hyperemia with regadenoson stress pose a concern for quantitative rubidium-82 PET imaging? Optimization of regadenoson PET imaging. JACC Cardiovasc Imaging 2015;8:448–50.
31. Dilsizian V, Gewirtz H, Paivanas N, et al. Serious and life threatening complications during cardiac stress testing: Potential mechanisms and management strategies. J Nucl Cardiol 2015;22:1198–213.
32. Bateman TM, Heller GV, McGhie AI, Friedman JD, Case JA, Bryngelson JR, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: Comparison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol 2006;13:24–33.
33. Beanlands RS, Chow BJ, Dick A, Friedrich MG, Gulenchyn KY, Kiess M, et al. Canadian Cardiovascular Society, Canadian Association of Radiologists, Canadian Association of Nuclear Medicine, Canadian Nuclear Cardiology Society, Canadian Society of Cardiac Magnetic Resonance. CCS/CAR/CANM/CNCS/CanSCMR joint position statement on advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multidetector computed tomographic angiography in the diagnosis and evaluation of ischemic heart disease-executive summary. Can J Cardiol 2007;23:107–19.
34. Dilsizian V, Taillefer R. Journey in evolution of nuclear cardiology: Will there be another quantum leap with the F-18 labeled myocardial perfusion tracers? JACC Cardiovasc Imaging 2012;5:1269–84.
35. Goldstein RA, Mullani NA, Marani SK, Fisher DJ, Gould KL, O’Brien HA Jr. Myocardial perfusion with rubidium-82. II. Effects of metabolic and pharmacologic interventions. J Nucl Med 1983;24:907–15.
36. Love WDB, Burch GE. Influence of the rate of coronary plasma on the extraction of rubidium-86 from coronary blood. Circ Res 1959;7:24–30.
37. Selwyn AP, Allan RM, L’Abbate A, Horlock P, Camici P, Clark J, et al. Relation between regional myocardial uptake of rubidium-82 and perfusion: Absolute reduction of cation uptake in ischemia. Am J Cardiol. 1982;50:112–21.
38. Senthamizhchelvan S, Bravo PE, Lodge MA, Merrill J, Bengel FM, Sgouros G. Radiation dosimetry of 82Rb in humans under pharmacologic stress. J Nucl Med 2011;52:485–91.
39. Hunter CR, Hill J, Ziadi MC, Beanlands RS, deKemp RA. Biodistribution and radiation dosimetry of (82)Rb at rest and during peak pharmacological stress in patients referred for myocardial perfusion imaging. Eur J Nucl Med Mol Imaging 2015;42:1032–42.
40. Hutchins GD, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl DE. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol 1990;15:1032–42.
41. Krivokapich J, Smith GT, Huang SC, Hoffman EJ, Ratib O, Phelps ME, et al. 13N-ammonia myocardial imaging at rest and with exercise in normal volunteers. Quantification of absolute myocardial perfusion with dynamic positron emission tomography. Circulation 1989;80:1328–37.
42. Bergmann SR, Hack S, Tewson T, Welch MJ, Sobel BE. The dependence of accumulation of 13N-ammonia by myocardium on metabolic factors and its implications for quantitative assessment of perfusion. Circulation 1980;61:34–43.
43. Kitsiou AN, Bacharach SL, Bartlett ML, Srinivasan G, Summers RM, Quyyumi AA, et al. 13N-ammonia myocardial blood flow and uptake: Relation to functional outcome of asynergic regions after revascularization. J Am Coll Cardiol 1999;33:678–86.
44. Krivokapich J, Huang SC, Phelps ME, MacDonald NS, Shine KI. Dependence of myocardial extraction and clearance on flow and metabolism. Am J Physiol 1982;242:H536–42.
45. Hajjiri MM, Leavitt MB, Zheng H, Spooner AE, Fischman AJ, Gewirtz H. Comparison of positron emission tomography measurement of adenosine-stimulated absolute myocardial blood flow versus relative myocardial tracer content for physiological assessment of coronary artery stenosis severity and location. JACC Cardiovasc Imaging 2009;2:751–8.
46. Schindler TH, Schelbert HR, Quercioli A, Dilsizian V. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. JACC Cardiovasc Imaging 2010;3:623–40.
47. Schelbert HR, Phelps ME, Huang SC, MacDonald NS, Hansen H, Selin C, et al. N- 13 ammonia as an indicator of myocardial blood flow. Circulation 1981;63:1259–72.
48. International Commission on Radiological Protection. Radiation dose to patients from radiopharmaceuticals: ICRP publication 80. Ann IRCP 2000;28:113.
49. 15 O. Circulation 1984;70:724–33.
50. Bergmann SR, Herrero P, Markham J, Weinheimer CJ, Walsh MN. Noninvasive quantitation of myocardial blood flow in human subjects with oxygen-15-labeled water and positron emission tomography. J Am Coll Cardiol 1989;14:639–52.
51. 15 O and dynamic positron-emission tomography. Strategy for quantification in relation to the partial-volume effect. Circulation 1988;78:104–15.
52. 2O PET imaging. J Am Coll Cardiol 2014;64:1464–75.
53. Schindler TH, Dilsizian V. PET-determined hyperemic myocardial blood flow: Further progress to clinical application. J Am Coll Cardiol 2014;64:1476–8.
54. Nekolla SG, Reder S, Saraste A, Higuchi T, Dzewas G, Preissel A, et al. Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: Comparison to 13N-ammonia and validation with microsphere in a pig model. Circulation 2009;119:2333–42.
55. Dilsizian V. SPECT and PET myocardial perfusion imaging: Tracers and techniques. In: Dilsizian V, Narula J, editors. Atlas of nuclear cardiology. New York: Springer; 2013. p. 55–94.
56. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res 1997;33:243–57.
57. Gropler RJ, Siegel BA, Lee KJ, Moerlein SM, Perry DJ, Bergmann SR, et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med 1990;31:1749–56.
58. Martin WH, Jones RC, Delbeke D, Sandler MP. A simplified intravenous glucose loading protocol for fluorine-18 fluorodeoxyglucose cardiac single-photon emission tomography. Eur J Nucl Med Mol Imaging 1997;24:1291–7.
59. Di Carli MF, Dorbala S, Meserve J, El Fakhri G, Sitek A, Moore SC. Clinical myocardial perfusion PET/CT. J Nucl Med 2007;48:783–93.
60. Strauss HW, Miller DD, Wittry MD, Cerqueira MD, Garcia EV, Iskandrian AS, et al. Procedure guideline for myocardial perfusion imaging 3.3. J Nucl Med Technol 2008;36:155–61.
61. Abraham A, Kass M, Ruddy TD, deKemp RA, Lee AK, Ling MC, et al. Right and left ventricular uptake with Rb-82 PET myocardial perfusion imaging: Markers of left main or 3 vessel disease. J Nucl Cardiol 2010;17:52–60.
62. Beanlands RS, Muzik O, Hutchins GD, Wolfe ER Jr, Schwaiger M. Heterogeneity of regional nitrogen 13-labeled ammonia tracer distribution in the normal human heart: Comparison with rubidium 82 and copper 62-labeled PTSM. J Nucl Cardiol 1994;1:225–35.
63. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. J Nucl Cardiol 2002;9:240–5.
64. Gould KL, Johnson N, Bateman T, Beanlands RS, Bengel FM, Bober R, et al. Anatomic versus physiologic assessment of coronary artery disease: Guiding management decisions using positron-emission tomography (PET) as a physiologic tool. J Am Coll Cardiol 2013;62:1639–53.
65. Dilsizian V, Narula J. Qualitative and quantitative scrutiny by regulatory process: Is the truth subjective or objective? JACC Cardiovasc Imaging 2009;2:1037–8.
66. Flachskampf FA, Dilsizian V. Leaning heavily on PET myocardial perfusion for prognosis. JACC Cardiovasc Imaging 2014;7:288–91.
67. Nesterov SV, Deshayes E, Sciagra R, Settimo L, Declerck JM, Pan XB, et al. Quantification of myocardial blood flow in absolute terms using (82) Rb PET imaging: The RUBY-10 Study. JACC Cardiovasc Imaging 2014;7:1119–27.
68. Nakazato R, Berman DS, Dey D, Le Meunier L, Hayes SW, Fermin JS, et al. Automated quantitative Rb-82 3D PET/CT myocardial perfusion imaging: Normal limits and correlation with invasive coronary angiography. J Nucl Cardiol 2012;19:265–76.
69. Santana CA, Folks RD, Garcia EV, Verdes L, Sanyal R, Hainer J, et al. Quantitative (82)Rb PET/CT: Development and validation of myocardial perfusion database. J Nucl Med 2007;48:1122–8.
70. Chander A, Brenner M, Lautamaki R, Voicu C, Merrill J, Bengel FM. Comparison of measures of left ventricular function from electrocardiographically gated 82 Rb PET with contrast-enhanced CT ventriculography: A hybrid PET/CT analysis. J Nucl Med 2008;49:1643–50.
71. Parkash R, deKemp RA, Ruddy TD, Kitsikis A, Hart R, Beauchesne L, et al. Potential utility of rubidium 82 PET quantification in patients with 3-vessel coronary artery disease. J Nucl Cardiol 2004;11:440–9.
72. Ziadi MC, deKemp RA, Williams K, Guo A, Renaud JM, Chow BJ, et al. Does quantification of myocardial flow reserve using rubidium-82 positron emission tomography facilitate detection of multivessel coronary artery disease? J Nucl Cardiol 2012;19:670–80.
73. 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol 2009;54:150–6.
74. Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Di Carli G, et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation 2011;124:2215–24.
75. Ziadi MC, deKemp RA, Williams KA, Guo A, Chow BJ, Renaud JM, et al. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. J Am Coll Cardiol 2011;58:740–8.
76. Lin JW, Laine AF, Akinboboye O, Bergmann SR. Use of wavelet transforms in analysis of time-activity data from cardiac PET. J Nucl Med 2001;42:194–200.
77. Lortie M, Beanlands RS, Yoshinaga K, Klein R, Dasilva JN, deKemp RA. Quantification of myocardial blood flow with 82Rb dynamic PET imaging. Eur J Nucl Med Mol Imaging 2007;34:1765–74.
78. El Fakhri G, Kardan A, Sitek A, Dorbala S, Abi-Hatem N, Lahoud Y, et al. Reproducibility and accuracy of quantitative myocardial blood flow assessment with (82)Rb PET: Comparison with (13)N-ammonia PET. J Nucl Med 2009;50:1062–71.
79. El Fakhri G, Sitek A, Guerin B, Kijewski MF, Di Carli MF, Moore SC. Quantitative dynamic cardiac 82Rb PET using generalized factor and compartment analyses. J Nucl Med 2005;46:1264–71.
80. Herrero P, Markham J, Shelton ME, Bergmann SR. Implementation and evaluation of a two-compartment model for quantification of myocardial perfusion with rubidium-82 and positron emission tomography. Circ Res 1992;70:496–507.
81. Herrero P, Markham J, Shelton ME, Weinheimer CJ, Bergmann SR. Noninvasive quantification of regional myocardial perfusion with rubidium-82 and positron emission tomography. Exploration of a mathematical model. Circulation 1990;82:1377–86.
82. Coxson PG, Huesman RH, Borland L. Consequences of using a simplified kinetic model for dynamic PET data. J Nucl Med 1997;38:660–7.
83. Yoshida K, Mullani N, Gould KL. Coronary flow and flow reserve by pet simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. J Nucl Med 1996;37:1701–12.
84. Dorbala S, Vangala D, Sampson U, Limaye A, Kwong R, Di Carli MF. Value of vasodilator left ventricular ejection fraction reserve in evaluating the magnitude of myocardium at risk and the extent of angiographic coronary artery disease: A 82Rb PET/CT study. J Nucl Med 2007;48:349–58.
85. Dorbala S, Hachamovitch R, Curillova Z, Thomas D, Vangala D, Kwong RY, et al. Incremental prognostic value of gated Rb-82 positron emission tomography myocardial perfusion imaging over clinical variables and rest LVEF. JACC Cardiovasc Imaging 2009;2:846–54.
86. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Ann Rev Physiol 1974;36:413–59.
87. Neely JR, Rovetto MJ, Oram JF. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis 1972;15:289–329.
88. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997;34:25–33.
89. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007;115:3213–23.
90. Taegtmeyer H, Dilsizian V. Imaging myocardial metabolism and ischemic memory. Nat Clin Pract Cardiovasc Med 2008;5(Suppl 2):S42–8.
91. Dilsizian V. FDG uptake as a surrogate marker for antecedent ischemia. J Nucl Med 2008;49:1909–11.
92. Kominsky DJ, Campbell EL, Colgan SP. Metabolic shifts in immunity and inflammation. J Immunol 2010;184:4062–8.
93. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier- added 2-[18f]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235–8.
94. International Commission on Radiation Protection ICRP. Radiation dose to patients from radiopharmaceuticals – addendum 3 to ICRP publication 53. ICRP publication 106. Ann. ICRP 38 (1-2), 2008. International Commission on Radiation Protection website. http://www.icrp.org/publication.asp?id=ICRP%20Publication%20106. Accessed November 30, 2015.
95. Choi Y, Brunken RC, Hawkins RA, Huang SC, Buxton DB, Hoh CK, et al. Factors affecting myocardial 2-[F-18] fluoro-2-deoxy-d-glucose uptake in positron emission tomography studies of normal humans. Eur J Nucl Med Mol Imaging 1993;20:308–18.
96. Knuuti MJ, Nuutila P, Ruotsalainen U, Saraste M, Härkönen R, Ahonen A, et al. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J Nucl Med 1992;33:1255–62.
97. Dilsizian V, editor. Myocardial viability: A clinical and scientific treatise. New York: Futura Publishing Company, Inc.; 2000.
98. Heller GV, Links J, Bateman TM, Ziffer JA, Ficaro E, Cohen MC, et al. American Society of Nuclear Cardiology and Society of Nuclear Medicine Joint Position Statement: Attenuation correction of myocardial perfusion SPECT scintigraphy. J Nucl Cardiol 2004;11:229–30.
99. Malkerneker D, Brenner R, Martin WH, Sampson UK, Feurer ID, Kronenberg MW, et al. CT-based attenuation correction versus prone imaging to decrease equivocal interpretations of rest/stress Tc-99m tetrofosmin SPECT MPI. J Nucl Cardiol 2007;14:314–23.
100. Sandler MP, Videlefsky S, Delbeke D, Patton JA, Meyerowitz C, Martin WH, et al. Evaluation of myocardial ischemia using a rest metabolism/stress perfusion protocol with fluorine-18-fluorodeoxyglucose/technetium-99m-MIBI and dual-isotope simultaneous-acquisition single-photon emission computed tomography. J Am Coll Cardiol 1995;26:870–6.
101. Bax JJ, Visser FC, Blanksma PK, Veening MA, Tan ES, Willemsen TM, et al. Comparison of myocardial uptake of fluorine-18-fluorodeoxyglucose imaged with PET and SPECT in dyssynergic myocardium. J Nucl Med 1996;37:1631–6.
102. Dilsizian V, Bacharach SL, Muang KM, Smith MF. Fluorine-18-deoxyglucose SPECT and coincidence imaging for myocardial viability: Clinical and technological issues. J Nucl Cardiol 2001;8:75–88.
103. Srinivasan G, Kitsiou AN, Bacharach SL, Bartlett ML, Miller-Davis C, Dilsizian V. 18F-fluorodeoxyglucose single photon emission computed tomography: Can it replace PET and thallium SPECT for the assessment of myocardial viability? Circulation 1998;97:843–50.
104. Vitale GD, deKemp RA, Ruddy TD, Williams K, Beanlands RS. Myocardial glucose utilization and optimization of (18)F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction. J Nucl Med 2001;42:1730–6.
105. Ratib O, Phelps ME, Huang SC, Henze E, Selin CE, Schelbert HR. Positron tomography with deoxyglucose for estimating local myocardial glucose metabolism. J Nucl Med 1982;23:577–86.
106. Choi Y, Hawkins RA, Huang SC, Gambhir SS, Brunken RC, Phelps ME, Schelbert HR. Parametric images of myocardial metabolic rate of glucose generated from dynamic cardiac PET and 2-[18f]fluoro-2-deoxy-d-glucose studies. J Nucl Med 1991;32:733–8.
107. Beanlands RS, Hendry PJ, Masters RG, deKemp RA, Woodend K, Ruddy TD. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging. Circulation 1998;98:II51–6.
108. Gerber BL, Ordoubadi FF, Wijns W, Vanoverschelde JL, Knuuti MJ, Janier M, et al. Positron emission tomography using (18)F-fluoro-deoxyglucose and euglycaemic hyperinsulinaemic glucose clamp: Optimal criteria for the prediction of recovery of post-ischaemic left ventricular dysfunction. Results from the European community concerted action multicenter study on use of (18)F-fluoro-deoxyglucose positron emission tomography for the detection of myocardial viability. Eur Heart J 2001;22:1691–701.
109. Marshall RC, Tillisch JH, Phelps ME, Huang SC, Carson R, Henze E, et al. Identification and differentiation of resting myocardial ischemia and infarction in man with positron computed tomography, 18F-labeled fluorodeoxyglucose and N-13 ammonia. Circulation 1983;67:766–78.
110. Schwartz E, Schaper J, vom Dahl J, Altehoefer C, Buell U, Schoendube F, et al. Myocardial hibernation is not sufficient to prevent morphological disarrangements with ischemic cell alterations and increased fibrosis. Circulation 1994;30:I-378.
111. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884–8.
112. vom Dahl J, Altehoefer C, Sheehan FH, Buechin P, Uebis R, Messmer BJ, et al. Recovery of regional left ventricular dysfunction after coronary revascularization. Impact of myocardial viability assessed by nuclear imaging and vessel patency at follow-up angiography. J Am Coll Cardiol 1996;28:948–58.
113. Thompson K, Saab G, Birnie D, Chow BJ, Ukkonen H, Ananthasubramaniam K, et al. Is septal glucose metabolism altered in patients with left bundle branch block and ischemic cardiomyopathy? J Nucl Med 2006;47:1763–8.
114. Ben-Haim S, Gacinovic S, Israel O. Cardiovascular infection and inflammation. Semin Nucl Med 2009;39:103–14.
115. James OG, Christensen JD, Wong TZ, Borges-Neto S, Koweek LM. Utility of FDG PET/CT in inflammatory cardiovascular disease. Radiographics 2011;31:1271–86.
116. Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol 2011;4:303–9.
117. Takano H, Nakagawa K, Ishio N, Daimon M, Daimon M, Kobayashi Y, et al. Active myocarditis in a patient with chronic active Epstein-Barr virus infection. Int J Cardiol 2008;130:e11–3.
118. Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2013;6:501–11.
119. 18F- fluorodeoxyglucose positron emission tomography: An autopsy case. Circulation 2010;122:535–6.
120. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: A clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978;58:1204–11.
121. Matsui Y, Iwai K, Tachibana T, Fruie T, Shigematsu N, Izumi T, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci 1976;278:455–69.
122. Hiraga H, Hiroe M, Iwai K, et al. Guideline for diagnosis of cardiac sarcoidosis: Study report on diffuse pulmonary diseases. Tokyo: The Japanese Ministry of Health and Welfare; 1993. p. 23–4 in Japanese.
123. Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord 2007;27:89–102.
124. Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 2010;3:1219–28.
125. Mc Ardle BA, Leung E, Ohira H, Cocker MS, deKemp RA, DaSilva J, et al. The role of (18F)-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis. J Nucl Cardiol 2013;20:297–306.
126. Schatka I, Bengel FM. Advanced imaging of cardiac sarcoidosis. J Nucl Med 2014;55:99–106.
127. 18F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep 2013;15:352.
128. 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012;53:241–8.
129. Birnie D. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11:1305–23.
130. 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008;35:933–41.
131. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy V, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329–36.
132. 18F-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009;16:801–10.
133. Harisankar CN, Mittal BR, Agrawal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol 2011;18:926–36.
134. 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol 2008;190:W151–6.
135. Lum DP, Wandell S, Ko J, Coel MN. Reduction of myocardial 2-deoxy-2-[18F] fluoro-d- glucose uptake artifacts in positron emission tomography using dietary carbohydrate restriction. Mol Imaging Biol 2002;4:232–7.
136. Persson E. Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragment (Fragmin). Acta Med Scand 1988;724:1–56.
137. Manabe O, Yoshinaga K, Ohira H, Masuda A, Sato T, Tsujino I, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial 18F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol 2015;23:244–52.
138. Asmal AC, Leary WP, Thandroyen F, Botha J, Wattrus S. A dose-response study of the anticoagulant and lipolytic activities of heparin in normal subjects. Br J Clin Pharmacol 1979;7:531–3.
139. Schleipman AR, Gerbaudo VH. Occupational radiation dosimetry assessment using an automated infusion device for positron-emitting radiotracers. J Nucl Med Technol 2012;40:244–8.
140. Blankstein R, Budoff MJ, Shaw LJ, Goff DC Jr, Polak JF, Lima J, et al. Predictors of coronary heart disease events among asymptomatic persons with low low-density lipoprotein cholesterol mesa (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 2011;58:364–74.
141. 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989–98.
142. Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, et al. Focal uptake on FDG PET tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005;26:1538–43.
143. Bartlett ML, Bacharach SL, Voipio-Pulkki LM, Dilsizian V. Artifactual inhomogeneities in myocardial PET and SPECT scans in normal subjects. J Nucl Med 1995;36:188–95.
144. Dweck MR, Jones C, Joshi NV, Fletcher AM, Richardson H, White A, et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation 2012;125:76–86.
145. Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M, et al. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Med 2014;21:925–39.
146. 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 2014;21:166–74.
147. Uslan DZ, Sohail MR, St Sauver JL, Friedman PA, Hayes DL, Stoner SM, et al. Permanent pacemaker and implantable cardioverter defibrillator infection: A population-based study. Arch Intern Med 2007;167:669–75.
148. Sandoe JA, Barlow G, Chambers JB, Gammage M, Guleri A, Howard P, et al. Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint working party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE). J Antimicrob Chemother 2015;70:325–59.
149. Chu VH, Crosslin DR, Friedman JY, Reed SD, Cabell CH, Griffiths RI, et al. Staphylococcus aureus bacteremia in patients with prosthetic devices: Costs and outcomes. Am J Med 2005;118:1416.
150. Chen W, Kim J, Molchanova-Cook OP, Dilsizian V. The potential of FDG PET/CT for early diagnosis of cardiac device and prosthetic valve infection before morphologic damages ensue. Curr Cardiol Rep 2014;16:459.
151. Bensimhon L, Lavergne T, Hugonnet F, Mainardi JL, Latremouille C, Maunoury C, et al. Whole body [(18) F] fluorodeoxyglucose positron emission tomography imaging for the diagnosis of pacemaker or implantable cardioverter defibrillator infection: A preliminary prospective study. Clin Microbiol Infect 2011;17:836–44.
152. Sarrazin JF, Philippon F, Tessier M, Guimond J, Molin F, Champagne J, et al. Usefulness of fluorine-18 positron emission tomography/computed tomography for identification of cardiovascular implantable electronic device infections. J Am Coll Cardiol 2012;59:1616–25.
153. 18F-fluorodeoxyglucose uptake as a novel major criterion. J Am Coll Cardiol 2013;61:2374–82.
154. Schouten LR, Verberne HJ, Bouma BJ, van Eck-Smit BL, Mulder BJ. Surgical glue for repair of the aortic root as a possible explanation for increased F-18 FDG uptake. J Nucl Cardiol 2008;15:146–7.
155. 18F-fluorodeoxyglucose PET/CT in prosthetic valve endocarditis. JACC Cardiovasc Imaging 2013;6:1020–1.
156. Pagano D, Townend JN, Littler WA, Horton R, Camici PG, Bonser RS. Coronary artery bypass surgery as treatment for ischemic heart failure: The predictive value of viability assessment with quantitative positron emission tomography for symptomatic and functional outcome. J Thorac Cardiovasc Surg 1998;115:791–9.
157. Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al. F-18-fluorodeoxyglucose positron emission tomography imaging- assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: A randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007;50:2002–12.
158. Di Carli MF, Davidson M, Little R, Khanna S, Mody FV, Brunken RC, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994;73:527–33.